Mimamsia was founded in 2018 with a vision to seek solutions for the patients suffering from rare hereditary disorders, where a positive patient story is the only way to drive our success. We aim to bring solutions in the forefront of all genetic testing whereby our success is defined solely in terms of positive outcomes. Mimamsia is the first company in genetic testing arena setting the industry trend to adopt an outcome based invoicing approach (no positive findings explaining the genetic etiology, no payment invoiced) that drives us to look deeply into the solution from a patient perspective rather than scratching the surface fast. Mimamsia ensures that the financial risk of not ending up with a diagnosis rests on us and not on our patients. Our services also include Life Sciences and Regulatory strategy consulting for labs in the biotech space.